Patents by Inventor Marcus Branschaedel
Marcus Branschaedel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10519217Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: GrantFiled: June 15, 2018Date of Patent: December 31, 2019Assignee: APOGENIX AGInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschaedel
-
Publication number: 20190016780Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: June 15, 2018Publication date: January 17, 2019Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschaedel
-
Patent number: 10000550Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: GrantFiled: December 2, 2016Date of Patent: June 19, 2018Assignee: Apogenix AGInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Publication number: 20170081386Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: December 2, 2016Publication date: March 23, 2017Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN, Marcus BRANSCHÄDEL
-
Patent number: 9527897Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: GrantFiled: December 14, 2015Date of Patent: December 27, 2016Assignee: Apogenix AGInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Patent number: 9469681Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: GrantFiled: January 21, 2014Date of Patent: October 18, 2016Assignee: APOGENIX AGInventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
-
Publication number: 20160176941Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: December 14, 2015Publication date: June 23, 2016Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN, Marcus BRANSCHÄDEL
-
Patent number: 9212211Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: GrantFiled: July 2, 2014Date of Patent: December 15, 2015Assignee: APOGENIX GMBHInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Publication number: 20150126710Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: ApplicationFiled: July 2, 2014Publication date: May 7, 2015Inventors: Oliver HILL, Marcus Branschädel, Christian Gieffers, Meinolf Thiemann
-
Publication number: 20150126709Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: July 2, 2014Publication date: May 7, 2015Inventors: Oliver HILL, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Patent number: 8907063Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: GrantFiled: February 25, 2013Date of Patent: December 9, 2014Assignee: Apogenix GmbHInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Publication number: 20140171622Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: ApplicationFiled: January 21, 2014Publication date: June 19, 2014Applicant: APOGENIX GMBHInventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
-
Patent number: 8664366Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: GrantFiled: January 9, 2009Date of Patent: March 4, 2014Assignee: Apogenix GmbHInventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
-
Patent number: 8383774Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: GrantFiled: July 10, 2008Date of Patent: February 26, 2013Assignee: Apogenix GmbHInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Publication number: 20120041181Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: ApplicationFiled: January 9, 2009Publication date: February 16, 2012Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
-
Publication number: 20110008326Abstract: The present invention relates to the use of an antigen-binding agent directed against human interleukin-4 receptor for the prevention and/or treatment of tumors, inflammatory and immunological disorders. Further the invention relates to methods of inhibiting the bioactivity of IL-4 without inhibiting binding of IL-4 to IL-4R and particularly to methods for treatment and/or prevention of tumors, inflammatory and immunological disorders, the methods comprising administering to an individual in need thereof an antigen-binding agent with binding affinity for IL-4R.Type: ApplicationFiled: March 30, 2009Publication date: January 13, 2011Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann, Christian Merz
-
Publication number: 20100199364Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: July 10, 2008Publication date: August 5, 2010Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel